A B Kimball1, A N Naegeli2, E Edson-Heredia2, C-Y Lin2, C Gaich2, E Nikaï2, K Wyrwich3, G Yosipovitch4. 1. Massachusetts General Hospital and Harvard Medical School, Boston, MA, U.S.A. 2. Eli Lilly and Company, Indianapolis, IN, U.S.A. 3. Evidera, Inc., Bethesda, MD, U.S.A. 4. Temple University, Philadelphia, PA, U.S.A.
Abstract
BACKGROUND: Itching is a profoundly distressing symptom for many patients with psoriasis, but it has not been rigorously studied using validated tools for this condition. OBJECTIVES: This study investigated the psychometric properties of the Itch Numeric Rating Scale (Itch NRS), a single-item patient-reported outcome (PRO) measuring the worst itching severity due to psoriasis in the past 24 h. METHODS: Using disease-specific clinician-rated and PRO data from one phase II and three phase III randomized clinical studies of subjects with moderate-to-severe plaque psoriasis, the Itch NRS was evaluated for test-retest reliability, construct validity and responsiveness. A responder definition was explored using anchor- and distribution-based methods. RESULTS: Test-retest reliability analyses supported the reproducibility of the measure (intraclass correlation coefficient range 0·71-0·74). To support the construct validity of the Itch NRS, large cross-sectional correlations with the Dermatology Life Quality Index (DLQI) Symptoms and Feelings domain (r ≥ 0·60 at baseline and r ≥ 0·80 at week 12) supported a priori hypotheses, while large correlations (r ≥ 0·71) between changes in Itch NRS scores and changes in DLQI Symptoms and Feelings domain scores from baseline to week 12 established responsiveness. A 4-point change was optimal for demonstrating a level of clinically meaningful improvement in itch severity after 12 weeks of treatment, which corresponds with marked clinical improvements in plaque psoriasis. CONCLUSIONS: The Itch NRS demonstrated sufficient reliability, validity and responsiveness, and appropriate interpretation standards for evaluating change over time in itch severity among patients with moderate-to-severe plaque psoriasis when validated using clinical trial data for this condition.
RCT Entities:
BACKGROUND:Itching is a profoundly distressing symptom for many patients with psoriasis, but it has not been rigorously studied using validated tools for this condition. OBJECTIVES: This study investigated the psychometric properties of the Itch Numeric Rating Scale (Itch NRS), a single-item patient-reported outcome (PRO) measuring the worst itching severity due to psoriasis in the past 24 h. METHODS: Using disease-specific clinician-rated and PRO data from one phase II and three phase III randomized clinical studies of subjects with moderate-to-severe plaque psoriasis, the Itch NRS was evaluated for test-retest reliability, construct validity and responsiveness. A responder definition was explored using anchor- and distribution-based methods. RESULTS: Test-retest reliability analyses supported the reproducibility of the measure (intraclass correlation coefficient range 0·71-0·74). To support the construct validity of the Itch NRS, large cross-sectional correlations with the Dermatology Life Quality Index (DLQI) Symptoms and Feelings domain (r ≥ 0·60 at baseline and r ≥ 0·80 at week 12) supported a priori hypotheses, while large correlations (r ≥ 0·71) between changes in Itch NRS scores and changes in DLQI Symptoms and Feelings domain scores from baseline to week 12 established responsiveness. A 4-point change was optimal for demonstrating a level of clinically meaningful improvement in itch severity after 12 weeks of treatment, which corresponds with marked clinical improvements in plaque psoriasis. CONCLUSIONS: The Itch NRS demonstrated sufficient reliability, validity and responsiveness, and appropriate interpretation standards for evaluating change over time in itch severity among patients with moderate-to-severe plaque psoriasis when validated using clinical trial data for this condition.
Authors: Mark G Lebwohl; Leon H Kircik; Angela Y Moore; Linda Stein Gold; Zoe D Draelos; Melinda J Gooderham; Kim A Papp; Jerry Bagel; Neal Bhatia; James Q Del Rosso; Laura K Ferris; Lawrence J Green; Adelaide A Hebert; Terry Jones; Steven E Kempers; David M Pariser; Paul S Yamauchi; Matthew Zirwas; Lorne Albrecht; Alim R Devani; Mark Lomaga; Amy Feng; Scott Snyder; Patrick Burnett; Robert C Higham; David R Berk Journal: JAMA Date: 2022-09-20 Impact factor: 157.335
Authors: Lluís Puig; Mark Lomaga; Kristin Hollister; Yves Dutronc; Lovisa Berggren; Peter C M van de Kerkhof Journal: Acta Derm Venereol Date: 2020-12-09 Impact factor: 3.875
Authors: Philip J Mease; Désirée van der Heijde; Christopher T Ritchlin; Masato Okada; Raquel S Cuchacovich; Catherine L Shuler; Chen-Yen Lin; Daniel K Braun; Chin H Lee; Dafna D Gladman Journal: Ann Rheum Dis Date: 2016-08-23 Impact factor: 19.103
Authors: Alice B Gottlieb; Brian Kirby; Caitriona Ryan; April N Naegeli; Russel Burge; Alison Potts Bleakman; Milena D Anatchkova; Gil Yosipovitch Journal: Dermatol Ther (Heidelb) Date: 2017-12-04
Authors: Gil Yosipovitch; Adam Reich; Martin Steinhoff; Anke Beselin; Toby Kent; Martin Dossenbach; Lovisa Berggren; Carsten Henneges; Thomas Luger Journal: Dermatol Ther (Heidelb) Date: 2018-11-21